Clinical trial · Interventional
Second Line ColoRectal Cancer Therapy in Combination With Combination of FOL- Folinic Acid(Leucovorin), F - Fluorouracil and OX - Oxaliplatin (FOLFOX)
A Study to Compare the Efficacy of AZD2171 in Combination With 5-fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX) and the Efficacy of Bevacizumab in Combination With FOLFOX in the Second-line Treatment of Patients With Metastatic Colorectal Cancer
NCT00278889CI-TRIAL-00008332HORIZON IcompletedPhase 2Results postedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The primary purpose of this study is to compare the efficacy of AZD2171 in combination with FOLFOX to the efficacy of bevacizumab in combination with FOLFOX, in the second-line treatment of patients with metastatic colorectal cancer
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Colorectal Cancer | Malignant Colorectal Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (5)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| 5-fluorouracil | Drug | Fluorouracil | ALIAS |
| AZD2171 | Drug | Cediranib | ALIAS |
| Bevacizumab | Drug | Bevacizumab | ALIAS |
| Leucovorin | Drug | Leucovorin | ALIAS |
| Oxaliplatin | Drug | Oxaliplatin | ALIAS |
Design
Arms and outcomes
Arms (2)
- type
- ACTIVE_COMPARATOR
- label
- 1
- description
- Bevacizumab + FOLFOX
- interventionNames
- Drug: 5-fluorouracil
- Drug: Leucovorin
- Drug: Oxaliplatin
- Drug: Bevacizumab
- type
- EXPERIMENTAL
- label
- 2
- description
- AZD2171 + FOLFOX
- interventionNames
- Drug: AZD2171
- Drug: 5-fluorouracil
- Drug: Leucovorin
- Drug: Oxaliplatin
Primary outcomes (1)
- measure
- Progression Free Survival
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Clinical diagnosis of colon or rectal cancer, * Received prior systemic therapy for cancer, * Cancer must have progressed during or after first treatment Exclusion Criteria: * Prior treatment with a VEGF inhibitor, * Poorly controlled hypertension
References
Publications (0)
Data not yet available
No reference posted for this study.